Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy
Publikation: Beitrag in Fachzeitschrift › Forschungsartikel › Beigetragen › Begutachtung
Beitragende
Abstract
Treatment with glatiramer acetate (GA) is thought to induce an in vivo change of the cytokine secretion pattern and the effector function of GA-reactive T helper (TH) cells (TH1-TH2-shift). Current theories propose that GA-reactive TH2 cells can penetrate the CNS, since they are activated by daily immunization. Inside the CNS, GA-reactive T cells may cross-react with products of the local myelin turnover presented by local antigen-presenting cells (APCs). Thus, some of the GA-specific TH2 cells may be stimulated to release anti-inflammatory cytokines inhibiting neighbouring inflammatory cells by a mechanism called bystander suppression. We demonstrate that both GA-specific TH2 and TH1 cells produce the neurotrophin brain-derived neurotrophic factor (BDNF). To demonstrate that GA-reactive T cells produce BDNF, we analyzed GA-specific, long-term T-cell lines (TCLs) and used a combination of reverse-transcription PCR and two specially designed techniques for BDNF protein detection: one was based on ELISA of supernatants from co-cultures of GA-specific TCLs plus GA-pulsed antigen-presenting cells, and the other, on the direct intracellular staining of BDNF in individual T cells and flow-cytometric analysis. The different assays and different TCLs yielded similar, consistent results. All GA-specific TH1, TH2 and TH0 lines could be stimulated to produce BDNF.
Details
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 109-112 |
Seitenumfang | 4 |
Fachzeitschrift | Journal of the Neurological Sciences |
Jahrgang | 233 |
Ausgabenummer | 1-2 |
Publikationsstatus | Veröffentlicht - 15 Juni 2005 |
Peer-Review-Status | Ja |
Externe IDs
PubMed | 15869765 |
---|---|
ORCID | /0000-0001-8799-8202/work/171553458 |
Schlagworte
ASJC Scopus Sachgebiete
Schlagwörter
- Brain-derived neurotrophic factor (BDNF), Glatiramer acetate, Immunmodulatory treatment, Multiple sclerosis, Neuroprotection, Neurotrophic factors